Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
  • TickerIPN
  • ISINFR0010259150
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Alexandre Iatrides ...
  • Christophe-Raphaël Ganet
  • Florent Laroche-Joubert
  • Jean Danjou
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Samantha Jeary

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/25/2020

...

Christophe-Raphaël Ganet

Ipsen : Trading update, guidance halted, forecasts and target price adjusted

>Fallout from COVID-19 “difficult to assess” - Ipsen published a press release where it warned its activity was hurt to varying degrees across the regions affected by COVID-19, the situation being very different from one country to another and constantly evolving. But thanks to a robust portfolio, the group believes the impact of the pandemic will remain limited.Nevertheless, amid a general economic slowdown, Ipsen's performance in China since the beginning of th...

Alexandre Iatrides ...
  • Christophe-Raphaël Ganet
  • Florent Laroche-Joubert
  • Jean Danjou
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Samantha Jeary

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/03/2020

...

Jérôme VINERIER

Short term view - IPSEN : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €116.00. The bearish trend would be challenged above €142.10.

Jérôme VINERIER

Analyse court terme - IPSEN : Les prix baissent.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 116,00 €. La tendance baissière serait remise en cause au-dessus de 142,10 €.

Jérôme VINERIER

Short term view - IPSEN : The trend is bearish.

The trend is bearish. The movement goes on. The next target is at €116.00, then €103.90. Passing €142.10 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - IPSEN : La tendance est baissière.

La tendance est baissière. Le mouvement se poursuit. Le prochain objectif est à 116,00 €, puis 103,90 €. Le franchissement de 142,10 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Analyse moyen terme - IPSEN : La baisse récente gagne en vigueur.

La tendance est haussière. La baisse récente gagne en vigueur. Le prochain support est à 115,64 €. La tendance serait remise en cause par la rupture de 96,60 €.

Eric Le Berrigaud

Ipsen: Exelixis’ Q2 figures: Cabometyx continues to grow, with plus and minus

Brief Comment - Ipsen: (BUY, Fair Value EUR150 (+6%)) Exelixis’ Q2 figures: Cabometyx continues to grow, with plus and minus

Christophe-Raphaël Ganet

Ipsen : Trading update, guidance halted, forecasts and target price adjusted

>Fallout from COVID-19 “difficult to assess” - Ipsen published a press release where it warned its activity was hurt to varying degrees across the regions affected by COVID-19, the situation being very different from one country to another and constantly evolving. But thanks to a robust portfolio, the group believes the impact of the pandemic will remain limited.Nevertheless, amid a general economic slowdown, Ipsen's performance in China since the beginning of th...

Christophe-Raphaël Ganet

Ipsen : Trading update et guidances suspendues – Prévisions et OC ajustées

>Impact COVID-19 « difficile à quantifier » - Ipsen publie un communiqué dans lequel il indique que ses activités sont affectées à divers degrés dans les zones géographiques touchées par le COVID-19, la situation étant très différente d’un pays à l’autre et en constante évolution. Mais grâce à un portefeuille robuste, le groupe juge que l’impact de cette pandémie restera limité. Néanmoins, compte tenu du ralentissement économique général, des performances d’Ipsen...

Eric Le Berrigaud

IPSEN NEUTRAL | EUR81 How much do disappointing US Cabometyx sales speak for Ipsen too?

Disappointing figures and trends for Cabometyx in the US What does this mean for Ipsen, if anything? CHECKMATE-9ER is the next significant catalyst here

Nurhayati Wan

Ipsen S.A.

Nurhayati Wan

Ipsen S.A.

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 24/10/2019 - Intrum, Ford - FR

Intrum (Achat) - 9M-19 : EBIT de SEK4,2 mds (€391m, +41,1%) Ford (Achat) : Abaisse ses perspectives pour 2019 Scor (Achat) - 9M-19 : Primes brutes de €12,1 mds (+3,2% à tcc) SEB (Achat) - 9M-19 : Résultat d’exploitation de SEK17,8 mds (€1,7 md, +4,8%) Constellium (Achat) : Revoit à la baisse ses objectifs 2019 Edenred (Achat) : Vise une croissance organique d’EBITDA >10% jusqu’à 2022 Europcar (Vente vs Achat) : Abaisse ses perspectives pour 2019 Schmolz + Bickenbach : Prévoit une augmentation de capital de CHF189m à CHF350m ...

Maxime Kogge

Ipsen : Un rendement faible mais suffisant vu le profil de risque équilibré. Achat confirmé sur l’obligation 2023

L’obligation Ipsen a connu un parcours satisfaisant depuis l’émission en 2016. La prime de 70bps sur les obligations BBB à l’émission s’est nettement resserrée jusqu’à fin 2018 dans un contexte d’aversion au risque. Toutefois, l’obligation affiche de nouveau depuis le début de l’année une prime de l’ordre de 40bps. Le newsflow a en effet été mitigé au S1 avec 1/ l’annonce de l’acquisition de Clementia, une opération prometteuse à long terme mais pénalisante à court terme sur les ...

Maxime Kogge

Ipsen : Low but sufficient yield in light of balanced risk profile. Buy confirmed on 2023 bond

The bond has seen a satisfactory track record since its 2016 issuance. The 70bp spread premium on the JPM 'BBB' index vs. the bond issue in June 2016 narrowed significantly until the end of 2018. However, the bond has anew offered a spread premium of around 40bps year to date. The newsflow was mixed with 1/ the announcement of the Clementia acquisition on 25 February, a promising deal in the long term but detrimental for ratios in the short term; 2/ an increase in the generic thr...

Ipsen : 2017 looks promising, after a record year in 2016

We have a stable credit opinion on the issuer. Ipsen had a record year in 2016, marked by strong sales growth in its specialty care division, driven by: 1. Somatuline’s commercial success, particularly in the US, and 2. gradual recovery in Primary care through its shift towards an OTx model. Despite investments to support the launch of Cabometyx®, profitability also improved in 2016. Ipsen is adopting a resolutely optimistic tone for the current year, expecting robust growth on the back of numerous ongoing developments. In addition, Ipsen has enriched its pipeline in Oncology and Neurosciences...

Ipsen : Un exercice 2017 prometteur, après une année 2016 record

Nous avons un avis crédit Stable sur l’émetteur. Ipsen a réalisé une année 2016 record, marquée par la forte croissance des ventes de sa division Médecine de Spécialité portée par : 1. le succès commercial de Somatuline notamment aux US, et 2. le redressement progressif de l’activité Médecine Générale grâce à son repositionnement vers un modèle OTx. Malgré les investissements consentis pour le lancement de Cabometyx®, la rentabilité a également progressé en 2016. Ipsen adopte un ton résolument optimiste pour cette année, attendue en forte croissance grâce aux nombreux développements en cours. ...

Alexandre Iatrides ...
  • Christophe-Raphaël Ganet
  • Florent Laroche-Joubert
  • Jean Danjou
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Samantha Jeary

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/25/2020

...

Alexandre Iatrides ...
  • Christophe-Raphaël Ganet
  • Florent Laroche-Joubert
  • Jean Danjou
  • Louis Boujard, CFA
  • Philippe Ourpatian
  • Samantha Jeary

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 25/03/2020

...

Alexandre Iatrides ...
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Jean Danjou
  • Jean Sassus
  • Johanna Jourdain
  • Laurence Hofmann
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/13/2020

...

Alexandre Iatrides ...
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Jean Danjou
  • Jean Sassus
  • Johanna Jourdain
  • Laurence Hofmann
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Tegner
  • Roland Pfaender,MBA,CFA,CCRA
  • Stephane Houri
  • Steven Gould
  • Sven Edelfelt
  • Virginie Rousseau
  • Yan Derocles

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 13/02/2020

...

Alfred Glaser ...
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Pierre Tegner
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 01/14/2020

...

Nurhayati Wan

Ipsen S.A.

Nurhayati Wan

Ipsen S.A.

Nurhayati Wan

Ipsen S.A.

Nurhayati Wan

Ipsen S.A.

Despite a better risk assessment and improving to Neutral, IPSEN SA remains under pressure

IPSEN SA (FR), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date October 8, 2019, the closing price was EUR 85.10 and its target price was estimated at EUR 76.36.

Charles Pinel

Ipsen - Assemblée générale des actionnaires du 28 mai 2019

Le conseil n'est pas majoritairement composé de membres libres de conflits d'intérêts. Par conséquent, parmi les renouvellements proposés, seul le Président du conseil sera soutenu en raison de la séparation des fonctions avec la Direction Générale (résolutions 5 à 7). En ce qui concerne la rémunération 2018 du Directeur Général, l'absence de communication des taux de réalisation de chacun des critères financiers du bonus constitue un manque rédhibitoire pour Proxinvest. Par ailleurs, l'attribution d'actions gratuites est basée sur des critères non vérifiables et qui sont calculés sur une pér...

Expert Corporate Governance Service (ECGS)

Ipsen -AGM and EGM 28 May 2019

The majority of the Board is not composed of independent members. Consequently, among the proposed renewals, only the Chairman of the Board will be supported due to the separation of functions with the Executive Management (resolutions 5 to 7). With regard to the 2018 remuneration of the CEO, the failure to communicate the achievement rates of each of the financial criteria related to the bonus constitutes a fundamental flaw for ECGS. In addition, the allocation of performance shares is based on criteria that cannot be verified and are calculated over a period of only two years, which is insu...

Ipsen – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Proxy Report - 30/05/2018

Board of directors (resolutions 4 to 9) The independence rate of the Board amounts to only 38.5%. Each of the three largest shareholders should have at least one representative regardless of the board's independence. Accordingly, we recommend that shareholders approve the re-election of Anne Beaufour but not Philippe Bonhomme. A new member, Paul Sekhri, is chairman of two listed companies and member of the Board of two others listed companies. Therefore, we have concerns about his time commitment. Remuneration (resolutions 10 to 13) The lack of disclosure of the achievement rates of each cr...

Charles Pinel

Proxy Report - 30/05/2018

Le conseil n'est pas majoritairement composé de membres libres de conflits d'intérêts. La politique de vote de Proxinvest accepte la présence au conseil des principaux actionnaires quelque soit l'indépendance du conseil. Par conséquent, nous recommandons l'approbation du renouvellement d'Anne Beaufour, actionnaire principal de la société via la société Mayroy, mais la nomination de Philippe Bonhomme, jusqu'alors représentant de Mayroy au conseil, ne pourra être soutenue. Par ailleurs, un des deux nouveaux membres indépendants - Paul Sekhri - détient un nombre de mandats trop important pour êtr...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch